1. Home
  2. Analysis
  3. Colistimethate-sodium
  4. Polyethylene-glycol-3350

Colistimethate sodium and Polyethylene glycol 3350 drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 14 people who take Colistimethate sodium and Polyethylene glycol 3350. Common interactions include weight increased among females, and rash maculo-papular among males.

The phase IV clinical study analyzes what interactions people who take Colistimethate sodium and Polyethylene glycol 3350 have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 25, 2023

14 people who take Colistimethate sodium and Polyethylene glycol 3350 together, and have interactions are studied.

What is Colistimethate sodium?

Colistimethate sodium has active ingredients of colistimethate sodium. Currently, eHealthMe is studying from 1,018 Colistimethate sodium users.

What is Polyethylene glycol 3350?

Polyethylene glycol 3350 has active ingredients of polyethylene glycol 3350. It is used in constipation. Currently, eHealthMe is studying from 3,163 Polyethylene glycol 3350 users.

Number of Colistimethate sodium and Polyethylene glycol 3350 reports submitted per year:

Colistimethate sodium and Polyethylene glycol 3350 drug interactions.

Common Colistimethate Sodium and Polyethylene Glycol 3350 drug interactions by gender *:

female:

  1. Weight increased

male:

  1. Rash maculo-papular
  2. Thrombocytopenia
  3. Leukocytosis
  4. Eosinophilia

Common Colistimethate Sodium and Polyethylene Glycol 3350 drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Weight increased

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Rash maculo-papular
  2. Thrombocytopenia
  3. Leukocytosis
  4. Eosinophilia

60+:

n/a

Common conditions people have *:

  1. Type 2 Diabetes: 11 people, 78.57%
  2. Sedation: 11 people, 78.57%
  3. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 7 people, 50.00%
  4. Diabetes: 2 people, 14.29%
  5. Chronic Respiratory Failure: 2 people, 14.29%
  6. Cystic Fibrosis (disease of the secretary glands): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Colistimethate sodium and Polyethylene glycol 3350?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Polyethylene glycol 3350 side effects:

Browse all side effects of Polyethylene glycol 3350:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Colistimethate sodium interactions:

Browse all interactions between Colistimethate sodium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Polyethylene glycol 3350 interactions:

Browse all interactions between Polyethylene glycol 3350 and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on colistimethate sodium and polyethylene glycol 3350 (the active ingredients of Colistimethate sodium and Polyethylene glycol 3350, respectively), and Colistimethate sodium and Polyethylene glycol 3350 (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Colistimethate sodium and Polyethylene glycol 3350.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.